Rick has 20+ years in commercial Healthcare and Life Sciences. In 2019 he founded NGS Reimbursement Solutions after 14+ years molecular diagnostic start-ups and platform companies, like CareDx, Novartis Dx, Verinata Health, Illumina, and Lexent Biosciences.

Since starting NGS Reimbursement Solutions he has advised investment firms, early-stage and established diagnostic and medical device companies.

Prior to that Rick was at Lexent Bio for 14 months, an early-stage start-up focused on tumor response to therapy and MRD. He was a member of the Executive Commercial leadership team, in his role of VP of Market Access he led the reimbursement, market access, policy, and evidence development vision, strategy, and operations. Lexent Bio was acquired in June 2020 by Foundation Medicine / Roche.

He has spent 10+ years in next generation sequencing (NGS) based diagnostics, with 7 years at Illumina as founding leader of its Global Market Access team. There he collaborated closely with customer labs to resolve Market Access and Reimbursement issues in Oncology, Women’s Health, and Rare Undiagnosed Genetic Disease markets.

Rick joined Illumina in 2013 as part of Illumina’s $450M acquisition of Verinata Health where he led the market access, payer relations, and reimbursement functions.

Prior to Verinata, he spent 2 years at Novartis Diagnostics where he developed a market access strategy framework integrated with product life-cycle planning.

Rick began his molecular diagnostics career at XDx (now CareDx), and during the ~3 years there he led the reimbursement, market access strategy and operations functions, reporting to the CEO.

He is an invited speaker and presents at national meetings on the rapidly changing dynamics of molecular diagnostics and genomic coverage, reimbursement, pricing, evidence development, and coding.